FFC#17/2015

Phage Therapy against Pseudomonas aeruginosa infections in Cystic Fibrosis patients

FFC#17/2015

Phage Therapy against Pseudomonas aeruginosa infections in Cystic Fibrosis patients

PRINCIPAL INVESTIGATOR

Daniela Erica Ghisotti (Dipartimento di Bioscienze – Università degli Studi di Milano)

RESEARCHERS

3

CATEGORY

AREA 3 Bronchopulmonary infection

DURATION

1 year

GOAL

€ 12.000 €

RESULTS

Some tens of phages were isolated and characterized and among them six were selected and mixed in a cocktail. This cocktail resulted able to efficiently kill different P. aeruginosa strains in vitro and to overcome bacterial biofilm. Genome analysis of phages sequences was carried out and indicated the absence of indesirable genes, suggesting phages could be used without problems for human therapy. Researchers’ intend now to validate the efficacy of the phage cocktail in two different models in vivo: in mice and in Galleria mellonella larvae. This strategy could have the potential for development as a therapeutic approach to control P. aeruginosa infections in CF patients.

OTHER RESULTS

FFC #3/2024

Two molecules are effective in activating Heat Shock Proteins and enhancing the action of CFTR correctors with the F508del mutation in vitro.

FFC#5/2024

Some peptide nucleic acids (PNAs) re-sensitise Pseudomonas aeruginosa to the antibiotic meropenem in vitro and reduce its virulence.

FFC#1/2023

Tezacaftor, one of the components of Kaftrio, induces an accumulation of dihydroceramides both in vitro and in vivo in animal models